OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Targeting Protein Kinases Degradation by PROTACs
Fei Yu, Ming Cai, Liang Shao, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 35
Fei Yu, Ming Cai, Liang Shao, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 35
Showing 1-25 of 35 citing articles:
E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers
Hong‐Beom Park, Kwang‐Hyun Baek
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 3, pp. 188736-188736
Closed Access | Times Cited: 84
Hong‐Beom Park, Kwang‐Hyun Baek
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 3, pp. 188736-188736
Closed Access | Times Cited: 84
Preclinical to clinical utility of ROCK inhibitors in cancer
Jaume Barcelo, Rémi Samain, Victoria Sanz‐Moreno
Trends in cancer (2023) Vol. 9, Iss. 3, pp. 250-263
Open Access | Times Cited: 55
Jaume Barcelo, Rémi Samain, Victoria Sanz‐Moreno
Trends in cancer (2023) Vol. 9, Iss. 3, pp. 250-263
Open Access | Times Cited: 55
Extracellular targeted protein degradation: an emerging modality for drug discovery
James A. Wells, Kaan Kumru
Nature Reviews Drug Discovery (2023) Vol. 23, Iss. 2, pp. 126-140
Closed Access | Times Cited: 43
James A. Wells, Kaan Kumru
Nature Reviews Drug Discovery (2023) Vol. 23, Iss. 2, pp. 126-140
Closed Access | Times Cited: 43
The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells
Alison Kurimchak, Carlos Herrera-Montávez, Sara Montserrat‐Sangrà, et al.
Science Signaling (2022) Vol. 15, Iss. 749
Open Access | Times Cited: 55
Alison Kurimchak, Carlos Herrera-Montávez, Sara Montserrat‐Sangrà, et al.
Science Signaling (2022) Vol. 15, Iss. 749
Open Access | Times Cited: 55
Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands
Hong‐Yi Zhao, Haipeng Wang, Yu-Ze Mao, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 6, pp. 4709-4726
Closed Access | Times Cited: 49
Hong‐Yi Zhao, Haipeng Wang, Yu-Ze Mao, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 6, pp. 4709-4726
Closed Access | Times Cited: 49
PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
Xin Han, Wenyi Wei, Yi Sun
Acta Materia Medica (2022) Vol. 1, Iss. 2
Open Access | Times Cited: 44
Xin Han, Wenyi Wei, Yi Sun
Acta Materia Medica (2022) Vol. 1, Iss. 2
Open Access | Times Cited: 44
Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy
Xin Han, Yi Sun
Cell Reports Physical Science (2022) Vol. 3, Iss. 10, pp. 101062-101062
Open Access | Times Cited: 38
Xin Han, Yi Sun
Cell Reports Physical Science (2022) Vol. 3, Iss. 10, pp. 101062-101062
Open Access | Times Cited: 38
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 23
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 23
Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019–2024)
Debasis Das, Lingzhi Xie, Hong Jian
RSC Medicinal Chemistry (2024)
Closed Access | Times Cited: 6
Debasis Das, Lingzhi Xie, Hong Jian
RSC Medicinal Chemistry (2024)
Closed Access | Times Cited: 6
Implications of frequent hitter E3 ligases in targeted protein degradation screens
Xiaoyu Zhang, Gabriel M. Simon, Benjamin F. Cravatt
Nature Chemical Biology (2025)
Closed Access
Xiaoyu Zhang, Gabriel M. Simon, Benjamin F. Cravatt
Nature Chemical Biology (2025)
Closed Access
Unraveling the Engagement of Kinases to CRBN Through a Shared Structural Motif to Optimize PROTACs Efficacy
Serena Rosignoli, Silvia Giordani, M Pacelli, et al.
Biomolecules (2025) Vol. 15, Iss. 2, pp. 206-206
Open Access
Serena Rosignoli, Silvia Giordani, M Pacelli, et al.
Biomolecules (2025) Vol. 15, Iss. 2, pp. 206-206
Open Access
Editorial: Exploring novel approaches to small molecule kinase inhibitors in cancer treatment
Anna Carbone, Rafael M. Couñago, Cristian O. Salas, et al.
Frontiers in Chemistry (2025) Vol. 13
Open Access
Anna Carbone, Rafael M. Couñago, Cristian O. Salas, et al.
Frontiers in Chemistry (2025) Vol. 13
Open Access
How many kinases are druggable? A review of our current understanding
Brian Anderson, Peter Rosston, Han Wee Ong, et al.
Biochemical Journal (2023) Vol. 480, Iss. 16, pp. 1331-1363
Open Access | Times Cited: 18
Brian Anderson, Peter Rosston, Han Wee Ong, et al.
Biochemical Journal (2023) Vol. 480, Iss. 16, pp. 1331-1363
Open Access | Times Cited: 18
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Hong‐Yi Zhao, Minhang Xin, San‐Qi Zhang
Drug Development Research (2023) Vol. 84, Iss. 2, pp. 337-394
Closed Access | Times Cited: 16
Hong‐Yi Zhao, Minhang Xin, San‐Qi Zhang
Drug Development Research (2023) Vol. 84, Iss. 2, pp. 337-394
Closed Access | Times Cited: 16
Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs)
Qisi Zhang, Cyrille S. Kounde, Milon Mondal, et al.
Chemical Communications (2022) Vol. 58, Iss. 78, pp. 10933-10936
Open Access | Times Cited: 25
Qisi Zhang, Cyrille S. Kounde, Milon Mondal, et al.
Chemical Communications (2022) Vol. 58, Iss. 78, pp. 10933-10936
Open Access | Times Cited: 25
Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the relationship between linker length, properties, and selective protein degradation
Robert J. Tokarski, Chia M. Sharpe, Andrew C. Huntsman, et al.
European Journal of Medicinal Chemistry (2023) Vol. 254, pp. 115342-115342
Closed Access | Times Cited: 12
Robert J. Tokarski, Chia M. Sharpe, Andrew C. Huntsman, et al.
European Journal of Medicinal Chemistry (2023) Vol. 254, pp. 115342-115342
Closed Access | Times Cited: 12
An Update on Protein Kinases as Therapeutic Targets—Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases
Shmuel Silnitsky, Samuel J. S. Rubin, Mulate Zerihun, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17600-17600
Open Access | Times Cited: 12
Shmuel Silnitsky, Samuel J. S. Rubin, Mulate Zerihun, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17600-17600
Open Access | Times Cited: 12
Targeting CDK4/6 for Anticancer Therapy
Jiating Qi, Zhuqing Ouyang
Biomedicines (2022) Vol. 10, Iss. 3, pp. 685-685
Open Access | Times Cited: 20
Jiating Qi, Zhuqing Ouyang
Biomedicines (2022) Vol. 10, Iss. 3, pp. 685-685
Open Access | Times Cited: 20
Discovery of FLT3-targeting PROTACs with potent antiproliferative activity against acute myeloid leukemia cells harboring FLT3 mutations
Zhijie Wang, Xun Lu, Canlin Liu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116237-116237
Closed Access | Times Cited: 2
Zhijie Wang, Xun Lu, Canlin Liu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116237-116237
Closed Access | Times Cited: 2
LIM Kinases, Promising but Reluctant Therapeutic Targets: Chemistry and Preclinical Validation In Vivo
Rayan Berabez, Sylvain Routier, Hélène Benedetti, et al.
Cells (2022) Vol. 11, Iss. 13, pp. 2090-2090
Open Access | Times Cited: 14
Rayan Berabez, Sylvain Routier, Hélène Benedetti, et al.
Cells (2022) Vol. 11, Iss. 13, pp. 2090-2090
Open Access | Times Cited: 14
Development and Utility of a PAK1-Selective Degrader
Hoi-Yee Chow, Sofiia Karchugina, Brian J. Groendyke, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 23, pp. 15627-15641
Open Access | Times Cited: 13
Hoi-Yee Chow, Sofiia Karchugina, Brian J. Groendyke, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 23, pp. 15627-15641
Open Access | Times Cited: 13
Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical
Yichao Kong, Caihong Jiang, Guifeng Wei, et al.
Molecules (2023) Vol. 28, Iss. 12, pp. 4672-4672
Open Access | Times Cited: 7
Yichao Kong, Caihong Jiang, Guifeng Wei, et al.
Molecules (2023) Vol. 28, Iss. 12, pp. 4672-4672
Open Access | Times Cited: 7
Protein kinases: The key contributors in pathogenesis and treatment of nonalcoholic fatty liver disease-derived hepatocellular carcinoma
Rong Liu, Mingping Qian, Ying‐Yu Cui
Metabolism (2023) Vol. 147, pp. 155665-155665
Closed Access | Times Cited: 7
Rong Liu, Mingping Qian, Ying‐Yu Cui
Metabolism (2023) Vol. 147, pp. 155665-155665
Closed Access | Times Cited: 7
Advanced approaches of developing targeted covalent drugs
Conghao Gai, Suzannah J. Harnor, Shihao Zhang, et al.
RSC Medicinal Chemistry (2022) Vol. 13, Iss. 12, pp. 1460-1475
Open Access | Times Cited: 12
Conghao Gai, Suzannah J. Harnor, Shihao Zhang, et al.
RSC Medicinal Chemistry (2022) Vol. 13, Iss. 12, pp. 1460-1475
Open Access | Times Cited: 12
Targeting Protein Kinases and Epigenetic Control as Combinatorial Therapy Options for Advanced Prostate Cancer Treatment
Soghra Bagheri, Mahdie Rahban, Fatemeh Bostanian, et al.
Pharmaceutics (2022) Vol. 14, Iss. 3, pp. 515-515
Open Access | Times Cited: 11
Soghra Bagheri, Mahdie Rahban, Fatemeh Bostanian, et al.
Pharmaceutics (2022) Vol. 14, Iss. 3, pp. 515-515
Open Access | Times Cited: 11